Howard Lee

Currently, Howard Lee is Chairman & Chief Executive Officer at TAHO Pharmaceuticals Ltd. since 2020, Chairman at Transwell Biotech Co. Ltd., Director at Waterstone Pharmaceuticals, Inc., Director at CryptoComm Partners LP, Independent Director at Amphastar Pharmaceuticals, Inc. since 2007, Independent Director at Sunko Ink Co., Ltd. since 2016, Independent Director at Genovate Biotechnology Co., Ltd. since 2020, Director at Development Center for Biotechnology, Director at Easywell Biomedicals, Inc., Independent Director at TaiMed Biologics, Inc. since 2017, Director-Supervisory Board at Epoch Foundation, Director-Supervisory Board at Association of Technology Managers In Taiwan, and Director at Magnifica, Inc. Formerly, Dr. Lee was President & Chief Executive Officer at CDIB Biotech USA Investment Co. Ltd. from 2000 to 2006, Director at International Medication Systems Ltd. from 1998 to 2002, Director at Optimer Pharmaceuticals LLC, Director at AVIVA Biosciences Corp., Director at InnoPharmax, Inc., Director at OBI Pharma, Inc., Managing Director at Silver Biotech Management, Inc. from 2006 to 2009, Independent Director at Kuo Ching Chemical Co., Ltd. from 2011 to 2018, Director at CapsoVision, Inc., Vice President at CDIB Capital Group from 1995 to 2006, Chief Investment Officer at UniMed Venture Management, Inc. from 2009 to 2010, and Partner at The CID Group (China) from 2012 to 2020.
Education includes undergraduate degree from Fu Jen Catholic University and graduate and doctorate degrees from the University of Southern California, both conferred in 1990.